Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors

Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedistat with docetaxel (arm 1, n = 22), carboplatin plus paclit...

Descripción completa

Detalles Bibliográficos
Autores principales: Lockhart, A Craig, Bauer, Todd M., Aggarwal, Charu, Lee, Carrie B., Harvey, R Donald, Cohen, Roger B., Sedarati, Farhad, Nip, Tsz Keung, Faessel, Hélène, Dash, Ajeeta B., Dezube, Bruce J., Faller, Douglas V., Dowlati, Afshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510847/
https://www.ncbi.nlm.nih.gov/pubmed/29781056
http://dx.doi.org/10.1007/s10637-018-0610-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510847/
https://www.ncbi.nlm.nih.gov/pubmed/29781056
http://dx.doi.org/10.1007/s10637-018-0610-0

Ejemplares similares